文献速递前列腺癌男科与性医学

GnRH拮抗剂与激动剂的心血管蛋白组学差异:一项II期随机试验的事后分析

Cardiovascular Proteomics: A Post Hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist vs GnRH Agonist among Men with Advanced Prostate Cancer.
PubMed 文献 · J Urol · 2021-05-25

该研究对80例晚期前列腺癌合并心血管疾病男性进行II期随机试验的事后蛋白组学分析,比较GnRH拮抗剂与激动剂治疗1年内188种心血管相关蛋白的变化。结果显示5种与斑块稳定性相关的蛋白在拮抗剂组随时间显著升高,支持GnRH拮抗剂对斑块稳定性的直接保护作用。

要点

  • GnRH拮抗剂组5种斑块稳定性相关蛋白水平随时间升高。
  • 结果提示拮抗剂直接保护斑块稳定性而非激动剂导致斑块破裂。
  • 该研究为假设生成性,需进一步确认。

核心结论

  • GnRH拮抗剂可能通过直接保护斑块稳定性降低心血管风险,而非GnRH激动剂导致斑块破裂。
  • 该研究为假设生成性,需进一步确认。

研究设计与样本

  • II期随机研究的事后蛋白组学分析,纳入80例晚期前列腺癌合并心血管疾病男性,随机接受GnRH激动剂(39例)或拮抗剂(41例)治疗1年。
  • 在基线及治疗后3、6、12个月采集血清,使用Olink Multiplex平台CV panel II和III检测188种蛋白。
  • 采用线性混合效应模型评估治疗效应,并用Benjamini-Hochberg法校正多重检验。

主要发现

  • 心血管蛋白组学分析纳入78例受试者的283份样本。
  • 鉴定出5种蛋白随时间变化模式在治疗组间存在差异:人壳三糖苷酶、巨噬细胞胶原结构受体、组织蛋白酶D、超氧化物歧化酶2和羟酸氧化酶1。
  • 上述5种蛋白均与斑块稳定性相关,且在GnRH拮抗剂组较激动剂组水平升高。

临床怎么用

  • 对于晚期前列腺癌合并心血管疾病的患者,GnRH拮抗剂可能具有斑块稳定性保护优势。
  • 该发现为假设生成性,临床决策需结合个体风险评估并等待进一步验证。

局限性

  • 本研究为II期随机试验的事后分析,样本量有限。
  • 结果为假设生成性,需进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recent studies demonstrated reduced cardiovascular (CV) risk with gonadotropin-releasing hormone (GnRH) antagonist, yet the underlying mechanism remains undetermined. The objective of this study was to examine longitudinal changes over time in established CV related proteins among men treated with GnRH agonists vs GnRH antagonist. MATERIALS AND METHODS: We performed a proteomics analysis of serum samples collected during a phase II randomized study among 80 men with advanced prostate cancer and preexisting CV disease who were randomized to receive a GnRH agonist (39) or GnRH antagonist (41) for 1 year. Serum samples were collected at baseline and at 3, 6 and 12 months following treatment, and analyzed levels of 188 proteins using the CV panel II and III of the Olink Multiplex platform (Olink Proteomics AB, Uppsala, Sweden). We fitted a linear mixed effects model to assess evidence of a treatment effect across CV related protein values. This included terms for treatment arm, protein levels and time-by-treatment interaction. Results were corrected for multiple testing using the Benjamini-Hochberg method. RESULTS: The CV proteomics analysis included 283 samples from 78 subjects. We identified 5 proteins with distinct patterns over time depending on study arm: human chitotriosidase, macrophage receptor with collagenous structure, cathepsin D, superoxide dismutase 2 and hydroxyacid oxidase 1. All 5 are associated with plaque stability and demonstrated an increased level among subjects in the GnRH antagonist arm compared to agonist. CONCLUSIONS: We compared longitudinal changes in CV proteins among men using androgen deprivation therapy. Our results support a direct protective effect of GnRH antagonist on plaque stability rather than a hazardous consequence of GnRH agonists on plaque rupture. This is a hypothesis generating study, and requires further confirmation.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lifshitz K, Ber Y, Shenhar C, et al. Cardiovascular Proteomics: A Post Hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist vs GnRH Agonist among Men with Advanced Prostate Cancer. J Urol. 2021. PMID: 34032505. doi:10.1097/JU.0000000000001879

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。